Antitumor activity against human promyelocytic leukemia and in silico studies of some benzoxazines


ÖKSÜZOĞLU E., YILMAZ S., YENİCE ÇAKMAK G., Ataei S., YILDIZ İ.

JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, cilt.41, sa.17, ss.8175-8190, 2023 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 41 Sayı: 17
  • Basım Tarihi: 2023
  • Doi Numarası: 10.1080/07391102.2022.2130989
  • Dergi Adı: JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, CAB Abstracts, Chemical Abstracts Core, EMBASE, MEDLINE
  • Sayfa Sayıları: ss.8175-8190
  • Anahtar Kelimeler: Benzoxazine, antitumor activity, HL-60 cell line, molecular docking, in silico ADMET, DNA TOPOISOMERASE-II, ANTIMICROBIAL ACTIVITY, INHIBITORS, ETOPOSIDE, AGONISTS, POTENT, CELLS, IDENTIFICATION, DERIVATIVES, CHALLENGES
  • Ankara Üniversitesi Adresli: Evet

Özet

Cancer is one of the deadliest diseases in the world today, and the incidence of cancer is increasing. Leukemia is a type of blood cancer defined as the uncontrolled proliferation of abnormal leukocytes in the blood and bone marrow. The HL-60 (human promyelocytic leukemia) cell line, derived from a single patient with acute promyelocytic leukemia, provides a unique in vitro model system for studying the cellular and molecular events involved in the proliferation and differentiation of leukemic cells. In this study, antitumor activities on the HL-60 of some of the resynthesized benzoxazine derivatives (BXN-01 and BXN-02) were investigated. The results of in vitro studies obtained were compared a standard drug, etoposide. In vitro results showed that BXN-01 and BXN-02 were found to be extremely effective compared to etoposide (IC50 value: 10 mu M) with IC50 values of 5 nM and 25 nM, respectively. Furthermore, molecular docking studies were carried out for preliminary prediction of possible interaction modes between compounds and the active site of the target macromolecules, hTopo II alpha, HDAC2, and RXRA. Then, in silico ADME/Tox studies were performed to predict drug-likeness and pharmacokinetic properties of BXN-01 and BXN-02. Communicated by Ramaswamy H. Sarma